News & articles
Tesamorelin10mg+Ipamorelin5mgTesamorelin and Ipamorelin dual-pathway GH stack. GHRH and ghrelin receptor activation from one vial.
Thymalin/ThymulinThymic bioregulator restoring T-lymphocyte function and immune competence. Classic compound in immune-rejuvenation programs.
TirzepatideDual GIP/GLP-1 agonist for advanced metabolic and weight-management protocols. One of the most studied incretin peptides in modern metabolic science.
VIPNeuro-immune peptide regulating tolerance, inflammation and circadian rhythm. Versatile support for autoimmune and CNS protocols.
GLP-1 Bulk-Drug Comment Period Closes; Thousands of Filings on 503B Peptide AccessFDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.
- FDA Advisory Panel Backs Six Peptides for 503A Bulks-List Consideration
The FDA Pharmacy Compounding Advisory Committee recommended six peptide bulk substances for 503A list consideration after two days of safety, sourcing, and dosing testimony in July 2026.
- Ketone Esters Plus Semaglutide: Preclinical Data on Muscle Preservation Draws Attention
Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.
- ENDO 2026: GLP-1 and Multi-Agonist Peptides Dominate Chicago Readouts
ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.